Jiangsu Xinke Pharmaceutical

Shanghai Xinke Pharmaceutical is a leading Chinese radiopharmaceutical company and a key subsidiary of Yantai Dongcheng Pharmaceutical Group. The company specializes in the development, production, and distribution of radioactive drugs for diagnostic imaging and cancer treatment. Its core product portfolio includes Technetium [99mTc] Sestamibi (99mTc-MIBI) for myocardial perfusion imaging, Urea [14C] breath test kits for Helicobacter pylori detection, and Iodine-125 radioactive seeds for brachytherapy. Shanghai Xinke operates a centralized production and supply network across China, including a significant presence in the Jiangsu region through its Suzhou branch, and is a major player in the domestic nuclear medicine market.